ALX Oncology has multiple 2026 catalysts for Evorpacept and ALX2004. Interim ASPEN-09 data are expected in Q3 2026, while an initial safety update from the phase 1 ALX2004 trial is expected in 1H 2026.
Scientists are testing experimental cancer therapies including mRNA therapeutic vaccines, engineered EcN bacteria that deliver romidepsin in mice, and macrophage-targeted CAR T cells.
Sift Biosciences, a UC Berkeley spinout, closed an oversubscribed $3.7 million pre-seed financing to advance its AI-driven peptide immunotherapy platform targeting immunologically "cold" solid tumors.
Researchers at Case Western Reserve University developed a method using ultrasound-activated nanobubbles to break down the collagen barriers surrounding solid tumors, enabling better drug delivery and immune cell penetration. The therapy could reach clinical trials within two years.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07407452 |
Iparomlimab and Tuvonralimab (QL1706) Combined With Standard Chemotherapy or Combined With Intraperitoneal Perfusion Chemotherapy and Olaparib as Neoadjuvant Therapy for Advanced Ovarian Cancer |
NOT_YET_RECRUITING | PHASE2 |
| NCT07219238 |
Study to Evaluate the Diagnostic Performance of GEH300079 (68Ga) Injection PET/CT for Detection of PC in Patients With Colorectal, Gastric, Ovarian, or Pancreatic Cancers (PERISCOPE) |
RECRUITING | PHASE2/PHASE3 |
| NCT06825455 |
Allogeneic B7H3 CAR-γδT Cell Therapy for Advanced Solid Tumors |
NOT_YET_RECRUITING | EARLY_PHASE1 |
| NCT05059782 |
Efficacy and Safety of Involving Field Radiotherapy in the Oligo-lesions(Metastasis/Recurrent/Refractory) of Ovarian Cancer |
UNKNOWN | NA |
| NCT03667417 |
Genetic Predisposition to Breast and Ovarian Cancer: Prospective Study of BRCAx Gene Mutation |
RECRUITING |
